GlassScriptPhysician profile
Kevin P Oconnor
NPI 1730173279
$1,708.71
in general payments reported to CMS, 2019-2025
33 companies · $222 in 2025
The $222 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $92.21 · 2021: $188 · 2022: $144 · 2023: $205 · 2024: $258 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $685.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $270.80 | 2019-2023 | Erleada |
| Pfizer INC. | $188.15 | 2019-2024 | |
| Astellas Pharma US INC | $131.96 | 2019-2023 | Myrbetriq |
| Neotract INC. | $109.55 | 2019 | |
| Boston Scientific Corporation | $96.43 | 2019 | |
| Sumitomo Pharma America, INC. | $96.22 | 2024-2025 | Gemtesa |
| Antares Pharma, INC. | $73.44 | 2019-2022 | |
| Urogen Pharma, INC. | $67.58 | 2024-2025 | |
| Endo Pharmaceuticals INC. | $66.35 | 2019-2020 | |
| Accord Healthcare, INC. | $58.95 | 2023-2024 | |
| Tolmar, INC. | $51.61 | 2023-2024 | |
| 180 Medical, INC. | $43.56 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.44 | 2021-2024 | |
| Myovant Sciences INC. | $39.30 | 2022 | |
| Immunitybio, INC. | $34.56 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| C. R. Bard, INC. & Subsidiaries | $27.61 | 2025 | |
| Blue Earth Diagnostics | $25.51 | 2021 | |
| Dendreon Pharmaceuticals LLC | $24.95 | 2019 | |
| Abbvie INC. | $24.41 | 2021 | |
| Endo USA, INC. | $22.08 | 2025 | Xiaflex |
| Photocure INC | $21.20 | 2019 | |
| Becton, Dickinson and Company | $20.74 | 2019 | |
| Verity Pharmaceuticals INC. | $18.95 | 2025 | Tlando |
| Ferring Pharmaceuticals INC. | $18.71 | 2025 | Adstiladrin |
| Alnylam Pharmaceuticals INC. | $17.41 | 2024 | Givlaari |
| Procept Biorobotics Corporation | $17.07 | 2023 | Aquabeam Robotic System |
| Azurity Pharmaceuticals, INC. | $16.53 | 2025 | Azmiro |
| Zyla Life Sciences, INC. | $16.25 | 2020 | |
| Allergan, INC. | $16.04 | 2019 | |
| Teleflex LLC | $14.84 | 2021 | |
| Myriad Genetic Laboratories, INC. | $14.02 | 2023 | Prolaris |
| Urovant Sciences INC | $12.89 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Oconnor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.